In a report released yesterday, Graham Parry from Bank of America Securities maintained a Sell rating on GlaxoSmithKline (GSK – Research Report), with a price target of p1,450.00. The company’s shares closed yesterday at $34.82.
Parry covers the Healthcare sector, focusing on stocks such as Sanofi, GlaxoSmithKline, and Novartis. According to TipRanks, Parry has an average return of 3.6% and a 55.00% success rate on recommended stocks.
GlaxoSmithKline has an analyst consensus of Hold, with a price target consensus of $19.66.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $46.05 and a one-year low of $27.92. Currently, GlaxoSmithKline has an average volume of 4.84M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Founded in 1715 and headquartered in Brentford, U.K., GlaxoSmithKline Plc is a global healthcare company which develops and manufactures pharmaceutical medicines in therapeutic areas, vaccines and consumer healthcare products in wellness, oral health, nutrition, and skin health categories.
Read More on GSK:
